Maximizing arsenic trioxide's anticancer potential: Targeted nanocarriers for solid tumor therapy

Area of Science:

• Oncology
• Nanomedicine
• Pharmacology

Background:

• Arsenic trioxide (ATO) is a potent anticancer agent, particularly effective against acute promyelocytic leukemia (APL).
• Clinical application of ATO for solid tumors is limited by rapid clearance, short half-life, severe adverse effects, and toxicity to normal cells.
• Nanomedicine presents a promising strategy to overcome these limitations through enhanced biocompatibility, targeting, and effectiveness.

Purpose of the Study:

• To review nanocarriers for targeted delivery of ATO to solid tumors.
• To detail the anticancer mechanisms of ATO.
• To discuss ATO's clinical trials, limitations, and combination therapies.

Main Methods:

• Literature review of nanocarrier systems for ATO delivery.
• Analysis of ATO's anticancer mechanisms and clinical data.
• Exploration of combination therapy strategies for ATO.

Main Results:

• Various nanocarriers have been developed for targeted ATO delivery to solid tumors.
• ATO exhibits potent anticancer activity through multiple mechanisms.
• Combination therapies can enhance ATO efficacy and reduce drug resistance.

Conclusions:

• Nanomedicine offers a viable approach to improve ATO's therapeutic index for solid tumors.
• Further research into targeted ATO delivery and combination therapies is warranted.
• ATO holds significant potential for solid tumor treatment when delivered via advanced nanocarrier systems.